ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Optimization and evaluation of different fast acting tablet formulations containing bisoprolol fumarate.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advanced Bisoprolol Oral Liquid Formulations for Flexible Pediatric and Geriatric Pharmacotherapy.AAPS PharmSciTech · 2026Article
- Development of Prolonged-Release Orodispersible Minitablets Containing Bisoprolol Fumarate.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study aimed to develop and evaluate orally disintegrating tablets (ODTs) and sublingual tablets (SLTs) containing Bisoprolol fumarate (BF) to enhance the onset of action and provided rapid relief of these cardiovascular diseases. For ODTs, experimental design was used to evaluate the effect of different independent factors on dissolution efficiency (DE%), disintegration time (DT), and hardness. Two independent variables, namely superdisintegrant concentration (crospovidone; CPV; X1) and taste masking agent concentration (Eudragit E100; X2) were selected to study their impact on the attributes of the BF ODTs. For SLTs, super disintegrant concentration (X1) and mixing time (X2) were selected to study their impact on SLTs attributes, as in the case of ODTs. The optimized ODTs formula (based on 8.3% CPV and 3.7% Eudragit) showed DE% of 85%, disintegration time (DT) of 39.3 s, and hardness of 2.55 Kp. Moreover, the optimized SLTs formula (based on 9.26% CPV and 16.2 min mixing time) showed DE% of 92%, DT was 35 s and hardness was 3.6 Kp. The optimized formula was compressed into an ODT and SLTs and studied according to USP criteria. All tablet examinations (Friability, Hardness, Disintegration Time, Drug Content, and Weight Variation) were within the accepted values and showed a high stability after six months of storage under accelerated conditions. The obtained results of the current study verified the efficacious formulation of BF as ODTs and SLTs to improve the onset of action and convalesce patient compliance in managing hypertension and arrhythmia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.